Hepatocellular carcinoma causes: Difference between revisions
Jump to navigation
Jump to search
m Bot: Removing from Primary care |
|||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Common causes of hepatocellular carcinoma include [[hepatitis B]], [[hepatitis C]], [[alcoholic liver cirrhosis]], [[hemochromatosis]], and [[hepatic porphyrias]]. | Common causes of hepatocellular carcinoma include [[hepatitis B]], [[hepatitis C]], [[alcoholic liver cirrhosis]], [[hemochromatosis]], and [[hepatic porphyrias]]. Other causes include [[Non-alcoholic fatty liver disease|non alcholic fatty liver disease]], [[NASH|non-alchoholic steatohepatitis]], and metabolic disorders as [[Diabetes mellitus type 2|diabetes mellitus type two]] and [[obesity]]. | ||
==Common Causes== | ==Common Causes== | ||
Common causes of hepatocellular carcinoma include the following:<ref name="JiangCenteno2018">{{cite journal|last1=Jiang|first1=Kun|last2=Centeno|first2=Barbara A.|title=Primary Liver Cancers, Part 2|journal=Cancer Control|volume=25|issue=1|year=2018|pages=107327481774465|issn=1073-2748|doi=10.1177/1073274817744658}}</ref><ref name="SaidGhufran2017">{{cite journal|last1=Said|first1=Adnan|last2=Ghufran|first2=Aiman|title=Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma|journal=World Journal of Clinical Oncology|volume=8|issue=6|year=2017|pages=429–436|issn=2218-4333|doi=10.5306/wjco.v8.i6.429}}</ref><ref name="pmid29199597">{{cite journal |vauthors=Erkekoglu P, Oral D, Chao MW, Kocer-Gumusel B |title=Hepatocellular Carcinoma and Possible Chemical and Biological Causes: A Review |journal=J. Environ. Pathol. Toxicol. Oncol. |volume=36 |issue=2 |pages=171–190 |year=2017 |pmid=29199597 |doi=10.1615/JEnvironPatholToxicolOncol.2017020927 |url=}}</ref> | Common causes of hepatocellular carcinoma include the following:<ref name="JiangCenteno2018">{{cite journal|last1=Jiang|first1=Kun|last2=Centeno|first2=Barbara A.|title=Primary Liver Cancers, Part 2|journal=Cancer Control|volume=25|issue=1|year=2018|pages=107327481774465|issn=1073-2748|doi=10.1177/1073274817744658}}</ref><ref name="SaidGhufran2017">{{cite journal|last1=Said|first1=Adnan|last2=Ghufran|first2=Aiman|title=Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma|journal=World Journal of Clinical Oncology|volume=8|issue=6|year=2017|pages=429–436|issn=2218-4333|doi=10.5306/wjco.v8.i6.429}}</ref><ref name="pmid29199597">{{cite journal |vauthors=Erkekoglu P, Oral D, Chao MW, Kocer-Gumusel B |title=Hepatocellular Carcinoma and Possible Chemical and Biological Causes: A Review |journal=J. Environ. Pathol. Toxicol. Oncol. |volume=36 |issue=2 |pages=171–190 |year=2017 |pmid=29199597 |doi=10.1615/JEnvironPatholToxicolOncol.2017020927 |url=}}</ref><ref name="FuWang2018">{{cite journal|last1=Fu|first1=Jing|last2=Wang|first2=Hongyang|title=Precision diagnosis and treatment of liver cancer in China|journal=Cancer Letters|volume=412|year=2018|pages=283–288|issn=03043835|doi=10.1016/j.canlet.2017.10.008}}</ref><ref name="pmid28989095">{{cite journal |vauthors=Fujiwara N, Friedman SL, Goossens N, Hoshida Y |title=Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine |journal=J. Hepatol. |volume= |issue= |pages= |year=2017 |pmid=28989095 |doi=10.1016/j.jhep.2017.09.016 |url=}}</ref><ref name="Parkin2006">{{cite journal|last1=Parkin|first1=Donald Maxwell|title=The global health burden of infection-associated cancers in the year 2002|journal=International Journal of Cancer|volume=118|issue=12|year=2006|pages=3030–3044|issn=0020-7136|doi=10.1002/ijc.21731}}</ref><ref name="ShiZhu2005">{{cite journal|last1=Shi|first1=J|last2=Zhu|first2=L|last3=Liu|first3=S|last4=Xie|first4=W-f|title=A meta-analysis of case–control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China|journal=British Journal of Cancer|volume=92|issue=3|year=2005|pages=607–612|issn=0007-0920|doi=10.1038/sj.bjc.6602333}}</ref> | ||
*[[Hepatitis B]] | *[[Hepatitis B]] | ||
*[[Hepatitis C]] | *[[Hepatitis C]] | ||
| Line 16: | Line 16: | ||
*[[Hepatic porphyrias]] ([[acute intermittent porphyria]], [[porphyria cutanea tarda]], [[hereditary coproporphyria]], and [[variegate porphyria]]) | *[[Hepatic porphyrias]] ([[acute intermittent porphyria]], [[porphyria cutanea tarda]], [[hereditary coproporphyria]], and [[variegate porphyria]]) | ||
*[[Tyrosinemia]] type 1 | *[[Tyrosinemia]] type 1 | ||
==Less common causes== | ==Less common causes== | ||
Less common causes of hepatocellular carcinoma include the following:<ref name="AgostiSabbà2018">{{cite journal|last1=Agosti|first1=Pasquale|last2=Sabbà|first2=Carlo|last3=Mazzocca|first3=Antonio|title=Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment|journal=Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease|volume=1864|issue=2|year=2018|pages=607–617|issn=09254439|doi=10.1016/j.bbadis.2017.11.026}}</ref><ref name="pmid29150490">{{cite journal |vauthors=Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA |title=Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma |journal=Gut |volume=67 |issue=2 |pages=380–388 |year=2018 |pmid=29150490 |doi=10.1136/gutjnl-2017-315068 |url=}}</ref><ref name="pmid29128083">{{cite journal |vauthors=Didi-Kouko Coulibaly J, Yeboua M, Kouassi Mbengue A, Kouadio EA, Anzouan-Kacou Kissi H, Binan AY, Lohoues Kouacou MJ, Attia A, N'Drin DY, Toutou T, Adoubi I, Pineau P |title=Evolution of hepatocellular carcinoma epidemiology in Côte d'Ivoire |journal=Bull Cancer |volume=104 |issue=11 |pages=937–945 |year=2017 |pmid=29128083 |doi=10.1016/j.bulcan.2017.09.010 |url=}}</ref> | Less common causes of hepatocellular carcinoma include the following:<ref name="AgostiSabbà2018">{{cite journal|last1=Agosti|first1=Pasquale|last2=Sabbà|first2=Carlo|last3=Mazzocca|first3=Antonio|title=Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment|journal=Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease|volume=1864|issue=2|year=2018|pages=607–617|issn=09254439|doi=10.1016/j.bbadis.2017.11.026}}</ref><ref name="pmid29150490">{{cite journal |vauthors=Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA |title=Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma |journal=Gut |volume=67 |issue=2 |pages=380–388 |year=2018 |pmid=29150490 |doi=10.1136/gutjnl-2017-315068 |url=}}</ref><ref name="pmid29128083">{{cite journal |vauthors=Didi-Kouko Coulibaly J, Yeboua M, Kouassi Mbengue A, Kouadio EA, Anzouan-Kacou Kissi H, Binan AY, Lohoues Kouacou MJ, Attia A, N'Drin DY, Toutou T, Adoubi I, Pineau P |title=Evolution of hepatocellular carcinoma epidemiology in Côte d'Ivoire |journal=Bull Cancer |volume=104 |issue=11 |pages=937–945 |year=2017 |pmid=29128083 |doi=10.1016/j.bulcan.2017.09.010 |url=}}</ref> | ||
*Non alcholic fatty liver disease(NAFLD) | *[[Non-alcoholic fatty liver disease|Non alcholic fatty liver disease(NAFLD)]] | ||
*Non alchoholic steatohepatitis(NASH) | *[[NASH|Non alchoholic steatohepatitis(NASH)]] | ||
*Metabolic disorders: | *Metabolic disorders: | ||
**Diabetes mellitus type II | **[[Diabetes mellitus type 2|Diabetes mellitus type II]] | ||
**Obesity | **[[Obesity]] | ||
**Metabolic syndrome | **[[Metabolic syndrome]] | ||
*Gut microbiota<ref name="pmid29163959">{{cite journal |vauthors=Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G |title=The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma |journal=United European Gastroenterol J |volume=5 |issue=7 |pages=944–953 |year=2017 |pmid=29163959 |pmc=5676553 |doi=10.1177/2050640617705576 |url=}}</ref> | *[[Gut microbiota]]<ref name="pmid29163959">{{cite journal |vauthors=Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G |title=The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma |journal=United European Gastroenterol J |volume=5 |issue=7 |pages=944–953 |year=2017 |pmid=29163959 |pmc=5676553 |doi=10.1177/2050640617705576 |url=}}</ref> | ||
==Drugs== | ==Drugs== | ||
| Line 43: | Line 44: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
[[Category:Emergency medicine]] | |||
Latest revision as of 22:07, 29 July 2020
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma causes On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma causes |
|
Risk calculators and risk factors for Hepatocellular carcinoma causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2] Mohamad Alkateb, MBBCh [3]
Overview
Common causes of hepatocellular carcinoma include hepatitis B, hepatitis C, alcoholic liver cirrhosis, hemochromatosis, and hepatic porphyrias. Other causes include non alcholic fatty liver disease, non-alchoholic steatohepatitis, and metabolic disorders as diabetes mellitus type two and obesity.
Common Causes
Common causes of hepatocellular carcinoma include the following:[1][2][3][4][5][6][7]
- Hepatitis B
- Hepatitis C
- Liver cirrhosis
- Aflatoxins
- Hemochromatosis
- Hepatic porphyrias (acute intermittent porphyria, porphyria cutanea tarda, hereditary coproporphyria, and variegate porphyria)
- Tyrosinemia type 1
Less common causes
Less common causes of hepatocellular carcinoma include the following:[8][9][10]
- Non alcholic fatty liver disease(NAFLD)
- Non alchoholic steatohepatitis(NASH)
- Metabolic disorders:
- Gut microbiota[11]
Drugs
The carcinogenic drugs for hepatocellular carcinoma are:
References
- ↑ Jiang, Kun; Centeno, Barbara A. (2018). "Primary Liver Cancers, Part 2". Cancer Control. 25 (1): 107327481774465. doi:10.1177/1073274817744658. ISSN 1073-2748.
- ↑ Said, Adnan; Ghufran, Aiman (2017). "Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma". World Journal of Clinical Oncology. 8 (6): 429–436. doi:10.5306/wjco.v8.i6.429. ISSN 2218-4333.
- ↑ Erkekoglu P, Oral D, Chao MW, Kocer-Gumusel B (2017). "Hepatocellular Carcinoma and Possible Chemical and Biological Causes: A Review". J. Environ. Pathol. Toxicol. Oncol. 36 (2): 171–190. doi:10.1615/JEnvironPatholToxicolOncol.2017020927. PMID 29199597.
- ↑ Fu, Jing; Wang, Hongyang (2018). "Precision diagnosis and treatment of liver cancer in China". Cancer Letters. 412: 283–288. doi:10.1016/j.canlet.2017.10.008. ISSN 0304-3835.
- ↑ Fujiwara N, Friedman SL, Goossens N, Hoshida Y (2017). "Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine". J. Hepatol. doi:10.1016/j.jhep.2017.09.016. PMID 28989095.
- ↑ Parkin, Donald Maxwell (2006). "The global health burden of infection-associated cancers in the year 2002". International Journal of Cancer. 118 (12): 3030–3044. doi:10.1002/ijc.21731. ISSN 0020-7136.
- ↑ Shi, J; Zhu, L; Liu, S; Xie, W-f (2005). "A meta-analysis of case–control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China". British Journal of Cancer. 92 (3): 607–612. doi:10.1038/sj.bjc.6602333. ISSN 0007-0920.
- ↑ Agosti, Pasquale; Sabbà, Carlo; Mazzocca, Antonio (2018). "Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864 (2): 607–617. doi:10.1016/j.bbadis.2017.11.026. ISSN 0925-4439.
- ↑ Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA (2018). "Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma". Gut. 67 (2): 380–388. doi:10.1136/gutjnl-2017-315068. PMID 29150490.
- ↑ Didi-Kouko Coulibaly J, Yeboua M, Kouassi Mbengue A, Kouadio EA, Anzouan-Kacou Kissi H, Binan AY, Lohoues Kouacou MJ, Attia A, N'Drin DY, Toutou T, Adoubi I, Pineau P (2017). "Evolution of hepatocellular carcinoma epidemiology in Côte d'Ivoire". Bull Cancer. 104 (11): 937–945. doi:10.1016/j.bulcan.2017.09.010. PMID 29128083.
- ↑ Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G (2017). "The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma". United European Gastroenterol J. 5 (7): 944–953. doi:10.1177/2050640617705576. PMC 5676553. PMID 29163959.